Revenue
2009
2010
2011
2012
2013
2019
2020
2021
2022
2023
2024
2025
Opus Genetics, Inc. (IRD)
Price$4.67Cached quote
Net income
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2009
2010
2011
2013
2014
2015
2016
2017
2018
2019
2020
Total cash / debt
CashTotal debt
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.2M | $11.0M | $19.0M | $39.9M | $589,000 | $0 | $3.0M | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | −$100,000 | — | — | — | — | — | — | — |
| Research & development | $30.8M | $26.9M | $17.7M | $14.4M | $15.2M | $6.6M | $2.4M | $13.1M | $10.7M | $10.1M | $12.1M | $7.0M | $3.3M | $3.4M | $12.0M | $3.9M | $3.2M | — | — | — | — | — | — | — |
| Operating expenses | $52.8M | $73.1M | $29.6M | $21.6M | $23.3M | $20.0M | $4.2M | $20.5M | $17.4M | $16.4M | $18.3M | $13.3M | $8.0M | $6.6M | $16.1M | $10.3M | $6.5M | — | — | — | — | — | — | — |
| Operating income | −$38.6M | −$62.1M | −$10.6M | $18.2M | −$22.7M | −$20.0M | −$4.2M | −$20.5M | −$17.4M | −$16.4M | −$18.3M | −$13.3M | −$8.0M | −$6.6M | −$16.1M | −$10.3M | −$6.5M | — | — | — | — | — | — | — |
| Operating margin | −271.90% | −564.72% | −55.45% | 45.74% | −3,854.84% | — | −139.77% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −$38.5M | −$62.1M | −$10.6M | $18.2M | −$22.7M | −$20.0M | −$4.2M | −$20.5M | −$17.3M | −$16.4M | −$18.2M | −$13.2M | −$7.9M | −$6.5M | −$16.1M | −$10.3M | −$6.4M | — | — | — | — | — | — | — |
| EBITDA margin | −271.53% | −564.63% | −55.42% | 45.75% | −3,854.16% | — | −138.40% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net income | −$49.6M | −$57.5M | −$10.0M | $17.9M | −$56.7M | −$24.6M | −$6.2M | −$14.4M | −$25.3M | −$9.3M | −$14.4M | −$18.5M | −$9.5M | −$6.2M | −$11.3M | −$14.0M | −$2.9M | −$3.7M | −$4.4M | −$6.5M | −$6.3M | −$3.3M | −$2.8M | −$1.2M |
| Net profit margin | −349.33% | −523.40% | −52.42% | 44.89% | −9,625.30% | — | −205.63% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic EPSper basic share | -$0.80 | -$2.15 | -$0.46 | $0.90 | -$3.82 | -$5.28 | -$2.17 | -$4.97 | -$10.49 | -$4.90 | -$9.01 | -$12.54 | -$7.98 | -$6.84 | -$13.68 | -$20.53 | -$5.70 | — | — | — | — | — | — | — |
| Diluted EPSper diluted share | -$0.80 | -$2.15 | -$0.46 | $0.87 | -$3.82 | -$5.28 | -$2.17 | -$4.97 | -$10.49 | -$4.90 | -$9.01 | -$12.54 | -$7.98 | -$6.84 | -$13.68 | -$20.53 | -$5.70 | — | — | — | — | — | — | — |
Owners
Reported shareholders
7.41%of listed shares
Nantahala Capital Management, LLC6.12M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Nantahala Capital Management, LLC | 7.41%6.12M shares |
Caligan Partners LP | 7.35%6.08M shares |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 7.30%6.03M shares |
Foundation Fighting Blindness Retinal Degeneration Fund / Foundation Fighting Blindness, Inc. | ≈4.59%3.79M shares |
BIOS Capital Management, LP | 4.46%3.68M shares |
BlackRock, Inc. | 3.77%3.12M shares |
Balyasny Asset Management L.P. | 3.74%3.09M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.58%2.96M shares |
Boxer Capital Management, LLC | 3.41%2.82M shares |
Trails Edge Capital Partners, LP | 3.32%2.74M shares |
MILLENNIUM MANAGEMENT LLC | 2.79%2.3M shares |
Gallagher Cam | ≈2.54%2.1M shares |
GREAT POINT PARTNERS LLC | 2.38%1.97M shares |
MARSHALL WACE, LLP | 2.35%1.95M shares |
ADAR1 Capital Management, LLC | 2.16%1.78M shares |
Magrath George | ≈2.11%1.74M shares |
GOLDMAN SACHS GROUP INC | 1.85%1.53M shares |
Woodline Partners LP | 1.74%1.43M shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.65%1.37M shares |
BOOTHBAY FUND MANAGEMENT, LLC | 1.44%1.19M shares |
Percentages use 82.65M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 18, 2026Form 4 | Foundation Fighting Blindness Retinal Degeneration Fund +1Director,Other | SellCommon Stock | 1.70M | $4.35 | $7.39M | 3.79M |
| Apr 23, 2026Form 4 | YERXA BENJAMIN RPresident | SellCommon Stock | 7.5K | $5.24 | $39.1K | 711.5K |
| Apr 23, 2026Form 4 | SCHACHLE JOSEPH KChief Operating Officer | SellCommon Stock | 4.7K | $5.22 | $24.5K | 296.1K |
| Apr 23, 2026Form 4 | Zaremba Rabourn AmyHead of Fin. Quality Assurance | SellCommon Stock | 1.6K | $5.20 | $8.5K | 188.7K |
| Apr 23, 2026Form 4 | Magrath GeorgeChief Executive Officer | SellCommon Stock | 9.5K | $5.22 | $49.6K | 1.74M |